Commit To Buy DexCom At $30, Earn 11.4% Annualized Using Options

Investors considering a purchase of DexCom ( DXCM) stock, but cautious about paying the going market price of $36.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $30 strike, which has a bid at the time of this writing of $2.25. Collecting that bid as the premium represents a 7.5% return against the $30 commitment, or a 11.4% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

Top YieldBoost Puts of the S&P 500 »

Selling a put does not give an investor access to DXCM's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $30 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless DexCom Inc sees its shares fall 17.5% and the contract is exercised (resulting in a cost basis of $27.75 per share before broker commissions, subtracting the $2.25 from $30), the only upside to the put seller is from collecting that premium for the 11.4% annualized rate of return.

Below is a chart showing the trailing twelve month trading history for DexCom Inc, and highlighting in green where the $30 strike is located relative to that history:

The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $30 strike for the 11.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for DexCom Inc (considering the last 252 trading day closing values as well as today's price of $36.38) to be 45%. For other put options contract ideas at the various different available expirations, visit the DXCM Stock Options page of

If you liked this article you might like

Apple Watch Is on Its Way to Becoming a $6 Billion Business, but Is That Really Enough?

DexCom Shares Rise After FDA Approves G5 Mobile App for Android Devices

Apple Watch Appears on Its Way to Becoming a $6 Billion Business

DexCom Stock Surging on Apple Watch Partnership

Markets Down? Get Used to It: Cramer's 'Mad Money' Recap (Wednesday 5/17/17)